The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
March 11, 2021 marks the first anniversary of a pandemic that has pushed the world into shutdown. Of a global population of almost 8 billion, COVID-19 has affected more than a hundred million people, with over 2 million deaths.1 However, the magnitude of its impact has been heterogeneous, with some groups, including patients with cancer, being more severely affected than others. With initially limited understanding of this infectious disease transmitted by a coronavirus strain, SARS-CoV-2, the World Health Organization (WHO) emerged as the global leader, despite the challenges. For specific disease groups, including cancer, scientific and professional societies such as the European Society for Medical Oncology (ESMO), rose to the challenge of providing recommendations to optimise multi-professional cancer treatment strategies during these unprecedented circumstances. From the perspective of minimising societal impact and subsequently finding a solution to the COVID-19 pandemic, transmission and protective measures were rapidly implemented. At the same time, manufacturers and regulators started the remarkably successful development of safe and effective vaccines.
Annals of Oncology , éditorial en libre accès, 2021